PUBLICATIONS 2007-2012
Strano S, Dell’Orso S, Mongiovì A, Monti O, Lapi E, Di Agostino S, Fontemaggi G and Blandino G. Mutant p53 proteins: between loss and gain of function Head and Neck 29:488-96, 2007
Strano S, Dell’Orso S, Di Agostino S, Fontemaggi G, Sacchi A, and Blandino G, Mutant p53: an oncogenic transcription factor. Oncogene 26:2212-9, 2007.
Weisz L, Damalas A, Liontos M, KarakaidosP, FontemaggiG, KalisM, Levrero M, StranoS, Gorgoulis W.G, RotterV, BlandinoG, OrenM. Mutant p53 enhances NF-kB activation by tumor necrosis factor alpha in cancer cells. Cancer Research 67:2396-401, 2007
Blandino G, Fanciulli M, Levrero M, Piaggio G. The Post Genomic Era: Workshop on Chromatin Immunoprecipitation related techniques. Cell. Death and Diff. 14:1390-1391, 2007
Mainardi S, Palescandolo E, Fontemaggi G, Diverio D, Grignani F, Testa U, Sacchi A, Lo Coco F, Levrero M, Blandino G* and Rizzo MG. DNp73 is a transcriptional target of PML/RAR??oncogene (*corresponding author) Cell Death and Differentiation 14:1968-71, 2007
Strano S, and Blandino G. YAP meets tumor suppression. Mol. Cell, 27:863-4, 2007
Puca R, Nardinocchi L, Gal H, Rechavi G, Amariglio N, Domany E, Notterman DA, Scarsella M, Leonetti C, Sacchi A, , Givol D, . Reversible dysfunction of wild-type p53 following homeodomain-interacting protein kinase-2 knockdown. Cancer Res. May 15;68(10):3707-14, 2008
Bossi G, Marampon F, Maor-Aloni R, Zani B, Rotter V, Oren M, , Blandino G., . Conditional RNA interference in vivo to study mutant p53 oncogenic gain of function on tumor malignancy. Cell Cycle. 2008 Jun 15;7(12):1870-9. Epub Jun 16, 2008
Di Agostino S, , Monti O, Dell'Orso S, Sacchi A, Eisenstein M, Citro G, Strano S, Blandino G. The disruption of the protein complex mutantp53/p73 increases selectively the response of tumor cells to anticancer drugs. Cell Cycle. 2008 Nov 1;7(21):3440-7. Epub Nov 16, 2008
. Mitosis poisons p53. Cell Cycle. Nov 1;7(21), 2008
Lapi E, Di Agostino S, Donzelli S, , Domany E, Rechavi G, Pandolfi PP, Givol D, , Lu X, Blandino G. PML, YAP, and p73 are components of a proapoptotic autoregulatory feedback loop. Dec 26;32(6):803-14, 2008
Donzelli S, Biagioni F, Fausti F, Strano S, Fontemaggi G, Blandino G. Oncogenomic Approaches in Exploring Gain of Function of Mutant p53. Curr Genomics. May;9(3):200-7, 2008
Benassi B, , Blandino G. Tetraploidy triggers mitochondria. Cell Cycle. May 1;8(9):1305-6, 2009
Blandino G, . p63 regulation by microRNAs. Cell Cycle. May 5;8(10):1466-7. Epub 2009 May 15, 2009
Haupt S, , Mizrahi I, , Voorhoeve M, , , Haupt Y. Promyelocytic leukemia protein is required for gain of function by mutant p53. Jun 1;69(11):4818-26, 2009
Bertini E, Oka T, Sudol M, Strano S, Blandino G. YAP: at the crossroad between transformation and tumor suppression. Cell Cycle. Jan 1;8(1):49-57. Epub Jan 24, 2009
Bon G, Di Carlo SE, Folgiero V, Avetrani P, Lazzari C, D'Orazi G, Brizzi MF, Sacchi A, Soddu S, Blandino G, Mottolese M, Falcioni R. Negative regulation of beta4 integrin transcription by homeodomain-interacting protein kinase 2 and p53 impairs tumor progression. Cancer Res. 2009 Jul 15;69(14):5978-86. Epub Jun 30, 2009
Muti P, Berrino F, Krogh V, Villarini A, Barba M, Strano S, Metformin, diet and breast cancer: an avenue for chemoprevention. Aug 15;8(16):2661. EpubAug 8, 2009
Careccia S, Mainardi S, Pelosi A, Gurtner A, Diverio D, Riccioni R, Testa U, Pelosi E, , Sacchi A, Lavorgna S, , , Levrero M, . A restricted signature of miRNAs distinguishes APL blasts from normal promyelocytes. Nov 12;28(45):4034-40. Epub Sep 14, 2009
Fontemaggi G, , Trisciuoglio D, , Melucci E, Fazi F, Terrenato I, , Muti P, Domany E, Del Bufalo D, Strano S, Blandino G. The execution of the transcriptional axis mutant p53, E2F1 and ID4 promotes tumor neo-angiogenesis. Nat Struct Mol Biol. 2009 Oct;16(10):1086-93. Epub Sep 27, 2009
Muscolini M, , , , Kamada R, Di Agostino S, Corazzari M, , Blandino G., Costanzo A, Sakaguchi K, Tuosto L. Characterization of a new cancer-associated mutant of p53 with a missense mutation (K351N) in the tetramerization domain. Cell Cycle. Oct 15;8(20):3396-405. Epub 2009 Oct 24, 2009
Barba M, Yang L, Schünemann HJ, Sperati F, Grioni S, Stranges S, Westerlind KC, Blandino G, Gallucci M, Lauria R, Malorni L, . Urinary estrogen metabolites and prostate cancer: a case-control study and meta-analysis. J Exp Clin Cancer Res. Oct 8;28:135, 2009
Blandino G, , Strano S, Sudol M, Yaffe M. The Hippo tumor suppressor pathway: a brainstorming workshop. Sci Signal. 2009 Nov 3;2(95):mr6, 2009
Stambolsky P, , Fontemaggi G, , Maor-Aloni R, Sigfried Z, , , Shay M, Kalo E, Blandino G, Simon I, Oren M, Rotter V. Modulation of the vitamin D3 response by cancer-associated mutant p53. Cancer Cell. Mar 16;17(3):273-85, 2010
Avraham R, Sas-Chen A, Manor O, Steinfeld I, Shalg Ri, Tarcic G, Bossel N, Zeisel A, Amit I, Enerly E, Russnes HG, Biagioni F, Mottolese M, Strano, Blandino G, Børresen-Dale A, Pilpel Y, Yakhini Z, Segal E and Yarden Y. EGF Decreases the abundance of microRNAs that restrain oncogenic transcription factors. Sci. Signal. Jun 1;3(124):ra43, 2010
Cioce M, Gherardi S, Viglietto G, Strano S, Blandino G, Muti P and Ciliberto G. Enriched mammosphere-forming cells from breast cancer cell lines as a tool for the identification of CSC-like targeting drugs. Cell Cycle, 2010 Jul 15;9(14):2878-87. Epub Jul 13, 2010
Bruno T, Desantis A, Bossi G, Di Agostino S, Sorino C, De Nicola F, Iezzi S, Franchitto A, Benassi B, Floridi A, Passananti C, Blandino G, and Fanciulli M. Che-1 depletion inhibits mutant p53 expression and activates p73-dependent apoptsosis by inducing endogenous DNA damage in human breast cancer. Cancer Cell, Aug 9;18(2):122-34, 2010
Slee E, Benassi B, Goldin R, Zhong S, Blandino G, and Lu X. Phosphorylation of Ser312 contributes to tumour suppression by p53 in vivo. Proc Natl Acad Sci U S A. 2010 Nov 9;107(45):19479-84. Epub Oct 20, 2010
Santoro R, Blandino G. p53: The pivot between cell cycle arrest and senescence. Cell Cycle, 2010 Nov;9(21):4262-3. Epub Nov 1, 2010
Fontemaggi G, Dell’Orso S, Muti P, Blandino G and StranoS. Id2 gene is a transcriptional target of the protein complex mutant p53/E2F1. Cell Cycle 2010 Jun 15;9(12):2464-6. Epub Jun 15, 2010
Strano S and Blandino G. Stability strengths oncogenic activity. Cell Cycle Apr 15;9(8):1458-9. Epub Apr 15, 2010
Goeman F, Blandino G. Novel insights into the cytoplasmic functions of p53. Cell Cycle. Jul 1;9(13):2498, 2010
Dell’Orso S, Ganci F, Strano S, Blandino G, and Fontemaggi G. ID-4: a new player in the cancer arena. Oncotarget. May;1(1):48-58, 2010
Dell’Orso S, Fontemaggi G, Stambolsky P, Goeman F, Voellenkle C, Damalas A, Levrero M, Strano S, Rotter V, Oren M and Blandino G. ChIP on chip analysis of in vivo mutantp53 binding to selected gene promoters.OMICS. May;15(5):305-12. Epub Feb 19, 2011
Muti P, Benassi B, Falvo E, Santoro R, Galanti S, Citro G, Carrubba G, Blandino G, and Strano S. Omics underpins novel clues on VDR chemoprevention target in breast cancer. OMICS. 2011 Jun;15(6):337-46. Epub Feb 24, 2011
Ganci F, Conti S, Fontemaggi G, Manciocco V, Donzelli S, Covello R, Muti P, Strano S, Blandino G, Spriano G. Allelic expression imbalance of TP53 mutated and polymorphic alleles in head and neck tumors. OMICS. 2011 Jun;15(6):375-81. Epub Feb 24, 2011
Testoni B, Guerrieri F, Gerbal-Choine S, Blandino G and Levrero M. p53-paralog DNp73 oncogene is repressed by IFNá/STAT2 through the recruitment of the Ezh2 Polycomb Group transcriptional repressor. Oncogene. 2011 Jun 9;30(23):2670-8. doi: 10.1038/onc.2010.635. Epub Mar 14, 2011
Sieri S, Muti P, Agnoli C, Berrino F, Pala V, Grioni S,Abagnato CA, Blandino G, Contiero P, Schunemann H, Krogh V. Prospective study on the role of glucose metabolism in breast cancer occurrence. Int J Cancer. 2011 Mar 16. doi: 10.1002/ijc.26071, 2011 (Epub ahead of print)
Testoni B, Voellenke C, Guerrieri F, Gerbal-Chaloin S, Blandino G, Levrero M. Chromatin dynamics of gene activation and repression in response to ifn{alpha} reveal new roles for phosphorylated and unphosphorylated forms of the transcription factor STAT2. J Biol Chem. 2011 Jun 10;286(23):20217-27. Epub Apr 15, 2011
McNeill H, Sudol M, Halder G, Strano S, Blandino G, Shaul YMeeting Report The Hippo tumor suppressor pathway: a report on the Second Workshop on the Hippo tumor suppressor pathway’.8Cell Death and Differentiation. Cell Death Differ. 2011 Aug;18(8):1388-90. doi: 10.1038/cdd.2011.61. Epub May 13, 2011
Di Agostino S, Strano S and Blandino G. YAP in Atlas Genetics. Oncology 2010 (in press)
Muscolini M, Montagni E, Palermo V, Di Agostino S, Gu W, Abdelmoula-Soussi S, Mazzoni C, Blandino G and Tuosto L. The cancer-associated K351N mutation affects the ubiquitination and the translocation to mitochondria of p53 protein. J. Biol. Chem. Sept 27,2011 (Epub ahead of print)
Botti E, Spallone G, Moretti F, Marinari B, Pinetti V, Galanti S, De Meo PD, De Nicola F, Ganci F, Castrignanò T, pesole G, Chimenti S, Guerrini L, Fanciulli M, Blandino G, Karin M, Costanzo A. Developmental factor IRF6 exhibits tumor suppressor activity in squamous cell carcinomas. Proc Natl Acad Sci U S A. Aug 16;108(33):13710-5. Epub Aug 1, 2011
Falvo E, Strigari L, Citro G, Giordano C, Arcangeli S, Soriani A, D’Alessia D, Muti P, Blandino G, Sperduti I, Pinnarò P. Dose and polymorphic genes xrcc1, xrcc3, gst paly a role in the risk of article developing erythema in breast cancer patients following single shot partial breast irradiation after conservative surgery. BMC Cancer. Jul 12;11:291, 2011
Santoro R, Marani M, Blandino G, Muti P, Strano S. Melatonin triggers p53 phosphorylation and prevents DNA damage accumulation. Oncogene Oct 17. doi: 10.1038/onc.2011.469, 2011(Epub ahead of print)
Blandino G, Deppert W, HainautP, Levine A, Lozano G, Olivier M, Rotter V, WimanK and Oren M. Mutant p53 protein, master regulator of human malignancies: a report on the fifth Mutant p53 Workshop. Cell Death & Differentiation (in press)
Canino C, Mori F, Cambria A, Diamantini A,Germoni S, Alessandrini G, Borsellino G, Galati R, Battistini L, Blandino R, Facciolo F, Citro G, Strano S, Muti P, Blandino G, Cioce M. SASP mediates chemoresistance and tumor-initiating-activity of Mesothelioma cells. Oncogene Oct 24. doi: 10.1038/onc.2011.485, 2011 (Epub ahead of print)
Cioce M, Canino C, Muti P, Strano S, Blandino G. Butein impairs the pro-tumorigenic activity of malignant pleural mesothelioma cells. Cell Cycle (accepted) Benassi B, Flavin R, Marchionni L, PanY, Chowdhury D, Marani M, Strano S, Muti P, Blandino G, and Loda M. c-Myc is activated via USP2a-mediated modulation of microRNAs in prostate cancer. Cancer Discovery (accepted)
Cioce M, Blandino G. PGC1áConfers Specificity - Metabolic Stress and p53-Dependent Transcription. Molecular Cell. 2011 (accepted)
Donzelli S, Fontemaggi G, Fazi F, Di Agostino S, Padula F, Biagioni F, Muti P, Strano S, Blandino G. microRNA-128-2 targets the transcriptional repressor E2F5 enhancing mutant p53 gain of function. Cell Death and Differentiation (in press)
Valenti F, Fausti F, Biagioni F, Fontemaggi G, Shay T, Domany E, Yaffe MB, Strano S, Blandino G, Di Agostino S. Mutant p53 oncogenic functions are sustained by plk2 kinase through an autoregulatory feedback loop. Cell Cycle (accepted)
Ciuffreda L, Di Sanza C, Cesta Incani U, Eramo A, Desideri M, Biagioni F, Passeri D, Bergamo P, Anichini A, Sabapathy K, McCubrey J, Ricciardi MR, Tafuri A, Blandino G, Orlandi A, Cognetti F, De Maria R, Del Bufalo D, Milella M. The mitogen activated protein kinase (MARK) cascade controls phosphatase and tensin homolog (PTEN) expression through multiple mechanisms. Journal of Molecular Medicine (accepted)